Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Association Scientific Sessions meeting.
The post Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial appeared first on MedCity News.
